Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Ligtenberg MA"'
Autor:
Vogelaar Ingrid P, van der Post Rachel S, Bisseling Tanya M, van Krieken J Han JM, Ligtenberg Marjolijn JL, Hoogerbrugge Nicoline
Publikováno v:
Hereditary Cancer in Clinical Practice, Vol 10, Iss 1, p 18 (2012)
Abstract Worldwide, gastric cancer is one of the most common forms of cancer, with a high morbidity and mortality. Several environmental factors predispose to the development of gastric cancer, such as Helicobacter pylori infection, diet and smoking.
Externí odkaz:
https://doaj.org/article/f9587e053cd54810b8b758e27f9e4ea3
Autor:
Sie Aisha S, Spruijt Liesbeth, van Zelst-Stams Wendy AG, Mensenkamp Arjen R, Ligtenberg Marjolijn J, Brunner Han G, Prins Judith B, Hoogerbrugge Nicoline
Publikováno v:
BMC Women's Health, Vol 12, Iss 1, p 12 (2012)
Abstract Background Current practice for patients with breast cancer referred for genetic counseling, includes face-to-face consultations with a genetic counselor prior to and following DNA-testing. This is based on guidelines regarding Huntington’
Externí odkaz:
https://doaj.org/article/a17623d49b8b473e8cc656ecbec12006
Autor:
Adang Eddy, Salemink Simone, van Duijvendijk Peter, Nagengast Fokko M, van der Weijden Trudy, Elwyn Glyn, Hermens Rosella PMG, Dekker Nicky, van Krieken J Han JM, Ligtenberg Marjolijn JL, Hoogerbrugge Nicoline
Publikováno v:
Implementation Science, Vol 5, Iss 1, p 6 (2010)
Abstract Background Individuals with multiple relatives with colorectal cancer (CRC) and/or a relative with early-onset CRC have an increased risk of developing CRC. They are eligible for preventive measures, such as surveillance by regular colonosco
Externí odkaz:
https://doaj.org/article/953f27101e074d2a9bf547111f5dc025
Autor:
Gómez García Encarna, van Os Theo A, Hogervorst Frans B, Verhoef Senno, Gille Johan J, Dommering Charlotte J, van der Luijt Rob B, Ausems Margreet G, Ligtenberg Marjolijn, Hoogerbrugge Nicoline, van der Hout Annemarie H, Oosterwijk Jan C, van den Ouweland Ans, Oldenburg Rogier, Vreeswijk Maaike P, Mohammadi Leila, Blok Marinus J, Wijnen Juul T, Helmer Quinta, Devilee Peter, van Asperen Christi J, van Houwelingen Hans C
Publikováno v:
BMC Cancer, Vol 9, Iss 1, p 211 (2009)
Abstract Background Assessment of the clinical significance of unclassified variants (UVs) identified in BRCA1 and BRCA2 is very important for genetic counselling. The analysis of co-segregation of the variant with the disease in families is a powerf
Externí odkaz:
https://doaj.org/article/5b24fbcfef5549b7a65cd823ecfc9509
Autor:
Vredevoogd DW; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Apriamashvili G; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Levy PL; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Sinha S; Cancer Data Science Laboratory, National Cancer Institute Center for Cancer Research, Bethesda, Maryland, USA., Huinen ZR; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Visser NL; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., de Bruijn B; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Boshuizen J; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., van Hal-van Veen SE; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Ligtenberg MA; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Bleijerveld OB; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Lin CP; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Díaz-Gómez J; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Sánchez SD; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Markovits E; Ella Lemelbaum Institute for Immuno-oncology, Sheba Medical Center, Tel Hashomer, Israel.; Department of Clinical Microbiology and Immunology, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel., Simon Nieto J; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., van Vliet A; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Krijgsman O; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands., Markel G; Department of Clinical Microbiology and Immunology, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.; Davidoff Center and Samueli Integrative Cancer Pioneering Center, Rabin Medical Center, Petah Tikva, Israel., Besser MJ; Department of Clinical Microbiology and Immunology, Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.; Davidoff Center and Samueli Integrative Cancer Pioneering Center, Rabin Medical Center, Petah Tikva, Israel.; Felsenstein Medical Research Center, The Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Altelaar M; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands.; Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Ruppin E; Cancer Data Science Laboratory, National Cancer Institute Center for Cancer Research, Bethesda, Maryland, USA., Peeper DS; Department of Molecular oncology and immunology, Netherlands Cancer Institute, Oncode Institute, Amsterdam, The Netherlands d.peeper@nki.nl.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Nov 07; Vol. 12 (11). Date of Electronic Publication: 2024 Nov 07.
Autor:
Lin CP; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Levy PL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Tumor Immunology and Immunotherapy Group, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain., Alflen A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Hematology and Medical Oncology, University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany; Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg-University, 55131 Mainz, Germany., Apriamashvili G; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Bleijerveld OB; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Alkan F; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Malka Y; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Hoekman L; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Markovits E; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel., George A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Traets JJH; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Vliet A; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Poźniak J; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Pulido-Vicuña CA; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van Hal-van Veen SE; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., van der Helm PW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Díaz-Gómez J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Warda H; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Behrens LM; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Mardesic P; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Dehni B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Visser NL; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Marine JC; Laboratory for Molecular Cancer Biology, VIB Center for Cancer Biology, 3000 Leuven, Belgium; Laboratory for Molecular Cancer Biology, Department of Oncology, KU Leuven, 3000 Leuven, Belgium., Markel G; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel., Faller WJ; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Altelaar M; Proteomics Facility, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Biomolecular Mass Spectrometry and Proteomics, Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, the Netherlands., Agami R; Division of Oncogenomics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands., Besser MJ; Ella Lemelbaum Institute for Immuno-oncology and Melanoma, Sheba Medical Center, Ramat Gan 52612, Israel; Department of Clinical Microbiology and Immunology, Faculty of Medicine, Tel Aviv University, Tel-Aviv 6997801, Israel; Davidoff Cancer Center and Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center, Petach Tikva 4941492, Israel; Felsenstein Medical Research Center, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands; Department of Pathology, VU University Amsterdam, 1081 HV Amsterdam, the Netherlands. Electronic address: d.peeper@nki.nl.
Publikováno v:
Cancer cell [Cancer Cell] 2024 Apr 08; Vol. 42 (4), pp. 623-645.e10. Date of Electronic Publication: 2024 Mar 14.
Autor:
Tong L; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Kremer V; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Neo SY; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Singapore Immunology Network, Agency for Science, Technology and Research, Singapore, Singapore., Liu Y; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Chen Y; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Medicine, Columbia University Irving Medical Center, New York, USA., Wagner AK; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Yang Y; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Chen Z; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Molecular Biology, Princeton University, New Jersey, USA., Seitz C; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Tobin NP; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Ligtenberg MA; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands., Alici E; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden., Chen X; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Haglund F; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Seliger B; Institute for Medical Immunology, Martin-Luther University Halle-Wittenberg, Halle, Germany.; Institute of Translational Immunology, Medical School Theodor Fontane, Brandenburg an der Havel, 14770, and Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany., Harmenberg U; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Colón E; Department of Women's and Children's Health, Karolinska Institutet and S:t Göran's Hospital-Unilabs, Stockholm, Sweden., Plogell AS; Department of Urology, Stockholm South General Hospital, Stockholm, Sweden., Liu LL; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden., Lundqvist A; Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Publikováno v:
Cancer communications (London, England) [Cancer Commun (Lond)] 2023 Jul; Vol. 43 (7), pp. 855-859. Date of Electronic Publication: 2023 Jun 14.
Autor:
Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Royen PT; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Rao D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Stunnenberg JA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lieftink C; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Morris B; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands., Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lacroix R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Shehwana H; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Ligtenberg MA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Beijersbergen RL; Robotics and Screening Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, the Netherlands., Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, the Netherlands., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.
Publikováno v:
Cancer immunology research [Cancer Immunol Res] 2023 Apr 03; Vol. 11 (4), pp. 450-465.
Autor:
Boshuizen J; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vredevoogd DW; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Krijgsman O; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Ligtenberg MA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Blankenstein S; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., de Bruijn B; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Frederick DT; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Kenski JCN; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Parren M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Brüggemann M; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Madu MF; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rozeman EA; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Song JY; Division of Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Horlings HM; Division of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Blank CU; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., van Akkooi ACJ; Division of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Flaherty KT; Department of Medical Oncology, Massachusetts General Hospital, Boston, MA, USA., Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Boston, MA, USA., Peeper DS; Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. d.peeper@nki.nl.
Publikováno v:
Nature communications [Nat Commun] 2023 Feb 07; Vol. 14 (1), pp. 672. Date of Electronic Publication: 2023 Feb 07.
Autor:
Rao D; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Lacroix R; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Rooker A; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Gomes T; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Stunnenberg JA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Valenti M; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Lin CP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., de Bruijn B; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Krijgsman O; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Ligtenberg MA; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam., Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam.; Oncode Institute, Utrecht., Blank CU; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam.; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam.; Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
Publikováno v:
Melanoma research [Melanoma Res] 2023 Feb 01; Vol. 33 (1), pp. 12-26. Date of Electronic Publication: 2022 Dec 20.